Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Bilir, Birdal ^a   Kucuk, Omer ^a,b   Moreno, Carlos S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

iCRT 3; SOX4; Triple negative breast cancer; Wnt signaling pathway

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GENISTEIN; INHIBITOR OF CATENIN RESPONSIVE TRANSCRIPTION 14; INHIBITOR OF CATENIN RESPONSIVE TRANSCRIPTION 3; INHIBITOR OF CATENIN RESPONSIVE TRANSCRIPTION 5; INHIBITOR OF WNT PRODUCTION 4; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX4; UNCLASSIFIED DRUG; XAV 939;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA PRIMERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICROSCOPY, CONFOCAL; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOXC TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT PROTEINS;

EID: 84886734493     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-280     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. 10.3322/caac.20138, 22237781.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109(9):1721-1728. 10.1002/cncr.22618, 17387718.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
5. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109(1):123-139. 10.1007/s10549-007-9632-6, 2443103, 17578664.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1):4429-4434.
7. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15(7):2302-2310. 10.1158/1078-0432.CCR-08-2132, 19318481.
8. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24(36):5652-5657. 10.1200/JCO.2006.06.5664, 17116942.
9. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20(12):1913-1927. 10.1093/annonc/mdp492, 19901010.
10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121(7):2750-2767. 10.1172/JCI45014, 3127435, 21633166.
11. Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol 2011, 23(6):566-577. 10.1097/CCO.0b013e32834bf8ae, 21986848.
12. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011, 30(43):4437-4446. 10.1038/onc.2011.145, 21532620.
13. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012, 209(4):679-696. 10.1084/jem.20111512, 3328367, 22430491.
14. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004, 3(1):36-41. 10.4161/cbt.3.1.561, 14739782.
15. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176(6):2911-2920. 10.2353/ajpath.2010.091125, 2877852, 20395444.
16. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17(1):9-26. 10.1016/j.devcel.2009.06.016, 2861485, 19619488.
17. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012, 4(5)
18. Moon RT. Wnt/beta-catenin pathway. Sciences STKE : Signal Transduction Knowl Environ 2005, 2005(271):cm1.
19. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008, 8(5):387-398. 10.1038/nrc2389, 18432252.
20. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002, 3(2):167-170. 10.1016/S1534-5807(02)00223-X, 12194848.
21. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009, 69(2):709-717. 10.1158/0008-5472.CAN-08-3415, 2629396, 19147588.
22. Wilson M, Koopman P. Matching SOX: partner proteins and co-factors of the SOX family of transcriptional regulators. Curr Opin Genet Dev 2002, 12(4):441-446. 10.1016/S0959-437X(02)00323-4, 12100890.
23. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007, 27(22):7802-7815. 10.1128/MCB.02179-06, 2169141, 17875931.
24. Cai H, Ni A, Li W, Li J. Inhibition of melanoma cell proliferation by targeting Wnt/beta-catenin pathway through Sox4 RNA interference. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban 2011, 31(4):565-569.
25. Lee AK, Ahn SG, Yoon JH, Kim SA. Sox4 stimulates beta-catenin activity through induction of CK2. Oncol Rep 2011, 25(2):559-565.
26. Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs 2000, 9(9):2103-2119. 10.1517/13543784.9.9.2103, 11060796.
27. Barnes S, Peterson TG. Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 1995, 208(1):103-108. 10.3181/00379727-208-43840, 7892283.
28. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest 2003, 21(5):744-757. 10.1081/CNV-120023773, 14628433.
29. Li Y, Wang Z, Kong D, Li R, Sarkar SH, Sarkar FH. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 2008, 283(41):27707-27716. 10.1074/jbc.M802759200, 2562074, 18687691.
30. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009, 21(11):1541-1547. 10.1016/j.cellsig.2009.03.009, 2756420, 19298854.
31. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis 2009, 30(2):331-339.
32. Su Y, Simmen FA, Xiao R, Simmen RC. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol Genomics 2007, 30(1):8-16. 10.1152/physiolgenomics.00023.2007, 17341692.
33. Shieh DB, Li RY, Liao JM, Chen GD, Liou YM. Effects of genistein on beta-catenin signaling and subcellular distribution of actin-binding proteins in human umbilical CD105-positive stromal cells. J Cell Physiol 2010, 223(2):423-434.
34. Park S, Choi J. Inhibition of beta-catenin/Tcf signaling by flavonoids. J Cell Biochem 2010, 110(6):1376-1385. 10.1002/jcb.22654, 20564233.
35. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A 2011, 108(15):5954-5963. 10.1073/pnas.1017496108, 3076864, 21393571.
36. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461(7264):614-620. 10.1038/nature08356, 19759537.
37. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5(2):100-107. 10.1038/nchembio.137, 2628455, 19125156.
38. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, OBrien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 2011, 4(177):ra41. 10.1126/scisignal.2001538, 21673316.
39. Hoeflich KP, OBrien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15(14):4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
40. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483(7391):603-607. 10.1038/nature11003, 3320027, 22460905.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.